Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10238796 | 0.89 | CHRNA7 (0.45) | CHRNA7CHRNB2CHRNA4UHRF1 | |
| SCHEMBL23207625 | 0.86 | CHRNA7 (0.50) | CHRNA7CHRNB2CHRNA4UHRF1NPC1 | |
| SCHEMBL19524970 | 0.82 | HTR2A (0.33) | CHRNA7NOS3NOS1NOS2CHRNB2 | |
| SCHEMBL19524957 | 0.81 | NOS3 (0.52) | NOS3NOS1NOS2CHRNB2CHRNA4 | |
| SCHEMBL19524994 | 0.78 | HRH3 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL10238795 | 0.74 | CHRNA7 (0.57) | CHRNA7CHRNB2CHRNA4UHRF1 | |
| SCHEMBL6845140 | 0.74 | CHRNA7 (0.57) | CHRNA7CHRNB2CHRNA4UHRF1 | |
| SCHEMBL16692314 | 0.73 | CHRNA7 (0.33) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL29792600 | 0.73 | CHRNA7 (0.44) | CHRNA7UHRF1 | |
| SCHEMBL23088396 | 0.73 | CHRNA7 (0.44) | CHRNA7UHRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2846794-B1 | BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20150126493-A1 | BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126493-A1 | BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | CHRNA7 1912/4885NOS3 2794/4885NOS1 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.